Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques

Augusto F. Schmidt, Paranthaman S. Kannan, James P. Bridges, Alyssa Filuta, Dakota Lipps, Matthew Kemp, Lisa Miller, Suhas G. Kallapur, Yan Xu, Jeffrey A. Whitsett, Alan H. Jobe

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Antenatal corticosteroids (ANS) are the major intervention to decrease respiratory distress syndrome and mortality from premature birth and are standard of care. The use of ANS is expanding to include new indications and gestational ages, although the recommended dosing was never optimized. The most widely used treatment is two intramuscular doses of a 1:1 mixture of betamethasone-phosphate (Beta-P) and betamethasone-acetate (Beta-Ac) – the clinical drug. We tested in a primate model the efficacy of the slow release Beta-Ac alone for enhancing fetal lung maturation and to reduce fetal corticosteroid exposure and potential toxic effects. Pregnant rhesus macaques at 127 days of gestation (80% of term) were treated with either the clinical drug (0.25 mg/kg) or Beta-Ac (0.125 mg/kg). Beta-Ac alone increased lung compliance and surfactant concentration in the fetal lung equivalently to the clinical drug. By transcriptome analyses the early suppression of genes associated with immune responses and developmental pathways were less affected by Beta-Ac than the clinical drug. Promoter and regulatory analysis prediction identified differentially expressed genes targeted by the glucocorticoid receptor in the lung. At 5 days the clinical drug suppressed genes associated with neuronal development and differentiation in the fetal hippocampus compared to control, while low dose Beta-Ac alone did not. A low dose ANS treatment with Beta-Ac should be assessed for efficacy in human trials.

Original languageEnglish (US)
Article number9039
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Macaca mulatta
Adrenal Cortex Hormones
Gene Expression
Lung
Pharmaceutical Preparations
Genes
Lung Compliance
Poisons
Glucocorticoid Receptors
Premature Birth
Gene Expression Profiling
Standard of Care
betamethasone acetate
Surface-Active Agents
Primates
Gestational Age
Hippocampus
Pregnancy
Mortality
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

Schmidt, A. F., Kannan, P. S., Bridges, J. P., Filuta, A., Lipps, D., Kemp, M., ... Jobe, A. H. (2019). Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques. Scientific reports, 9(1), [9039]. https://doi.org/10.1038/s41598-019-45171-6

Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques. / Schmidt, Augusto F.; Kannan, Paranthaman S.; Bridges, James P.; Filuta, Alyssa; Lipps, Dakota; Kemp, Matthew; Miller, Lisa; Kallapur, Suhas G.; Xu, Yan; Whitsett, Jeffrey A.; Jobe, Alan H.

In: Scientific reports, Vol. 9, No. 1, 9039, 01.12.2019.

Research output: Contribution to journalArticle

Schmidt, AF, Kannan, PS, Bridges, JP, Filuta, A, Lipps, D, Kemp, M, Miller, L, Kallapur, SG, Xu, Y, Whitsett, JA & Jobe, AH 2019, 'Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques', Scientific reports, vol. 9, no. 1, 9039. https://doi.org/10.1038/s41598-019-45171-6
Schmidt, Augusto F. ; Kannan, Paranthaman S. ; Bridges, James P. ; Filuta, Alyssa ; Lipps, Dakota ; Kemp, Matthew ; Miller, Lisa ; Kallapur, Suhas G. ; Xu, Yan ; Whitsett, Jeffrey A. ; Jobe, Alan H. / Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{ddf4c7bd180d4cabaa382d546b41dfd7,
title = "Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques",
abstract = "Antenatal corticosteroids (ANS) are the major intervention to decrease respiratory distress syndrome and mortality from premature birth and are standard of care. The use of ANS is expanding to include new indications and gestational ages, although the recommended dosing was never optimized. The most widely used treatment is two intramuscular doses of a 1:1 mixture of betamethasone-phosphate (Beta-P) and betamethasone-acetate (Beta-Ac) – the clinical drug. We tested in a primate model the efficacy of the slow release Beta-Ac alone for enhancing fetal lung maturation and to reduce fetal corticosteroid exposure and potential toxic effects. Pregnant rhesus macaques at 127 days of gestation (80{\%} of term) were treated with either the clinical drug (0.25 mg/kg) or Beta-Ac (0.125 mg/kg). Beta-Ac alone increased lung compliance and surfactant concentration in the fetal lung equivalently to the clinical drug. By transcriptome analyses the early suppression of genes associated with immune responses and developmental pathways were less affected by Beta-Ac than the clinical drug. Promoter and regulatory analysis prediction identified differentially expressed genes targeted by the glucocorticoid receptor in the lung. At 5 days the clinical drug suppressed genes associated with neuronal development and differentiation in the fetal hippocampus compared to control, while low dose Beta-Ac alone did not. A low dose ANS treatment with Beta-Ac should be assessed for efficacy in human trials.",
author = "Schmidt, {Augusto F.} and Kannan, {Paranthaman S.} and Bridges, {James P.} and Alyssa Filuta and Dakota Lipps and Matthew Kemp and Lisa Miller and Kallapur, {Suhas G.} and Yan Xu and Whitsett, {Jeffrey A.} and Jobe, {Alan H.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-019-45171-6",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Dosing and formulation of antenatal corticosteroids for fetal lung maturation and gene expression in rhesus macaques

AU - Schmidt, Augusto F.

AU - Kannan, Paranthaman S.

AU - Bridges, James P.

AU - Filuta, Alyssa

AU - Lipps, Dakota

AU - Kemp, Matthew

AU - Miller, Lisa

AU - Kallapur, Suhas G.

AU - Xu, Yan

AU - Whitsett, Jeffrey A.

AU - Jobe, Alan H.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Antenatal corticosteroids (ANS) are the major intervention to decrease respiratory distress syndrome and mortality from premature birth and are standard of care. The use of ANS is expanding to include new indications and gestational ages, although the recommended dosing was never optimized. The most widely used treatment is two intramuscular doses of a 1:1 mixture of betamethasone-phosphate (Beta-P) and betamethasone-acetate (Beta-Ac) – the clinical drug. We tested in a primate model the efficacy of the slow release Beta-Ac alone for enhancing fetal lung maturation and to reduce fetal corticosteroid exposure and potential toxic effects. Pregnant rhesus macaques at 127 days of gestation (80% of term) were treated with either the clinical drug (0.25 mg/kg) or Beta-Ac (0.125 mg/kg). Beta-Ac alone increased lung compliance and surfactant concentration in the fetal lung equivalently to the clinical drug. By transcriptome analyses the early suppression of genes associated with immune responses and developmental pathways were less affected by Beta-Ac than the clinical drug. Promoter and regulatory analysis prediction identified differentially expressed genes targeted by the glucocorticoid receptor in the lung. At 5 days the clinical drug suppressed genes associated with neuronal development and differentiation in the fetal hippocampus compared to control, while low dose Beta-Ac alone did not. A low dose ANS treatment with Beta-Ac should be assessed for efficacy in human trials.

AB - Antenatal corticosteroids (ANS) are the major intervention to decrease respiratory distress syndrome and mortality from premature birth and are standard of care. The use of ANS is expanding to include new indications and gestational ages, although the recommended dosing was never optimized. The most widely used treatment is two intramuscular doses of a 1:1 mixture of betamethasone-phosphate (Beta-P) and betamethasone-acetate (Beta-Ac) – the clinical drug. We tested in a primate model the efficacy of the slow release Beta-Ac alone for enhancing fetal lung maturation and to reduce fetal corticosteroid exposure and potential toxic effects. Pregnant rhesus macaques at 127 days of gestation (80% of term) were treated with either the clinical drug (0.25 mg/kg) or Beta-Ac (0.125 mg/kg). Beta-Ac alone increased lung compliance and surfactant concentration in the fetal lung equivalently to the clinical drug. By transcriptome analyses the early suppression of genes associated with immune responses and developmental pathways were less affected by Beta-Ac than the clinical drug. Promoter and regulatory analysis prediction identified differentially expressed genes targeted by the glucocorticoid receptor in the lung. At 5 days the clinical drug suppressed genes associated with neuronal development and differentiation in the fetal hippocampus compared to control, while low dose Beta-Ac alone did not. A low dose ANS treatment with Beta-Ac should be assessed for efficacy in human trials.

UR - http://www.scopus.com/inward/record.url?scp=85067811373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067811373&partnerID=8YFLogxK

U2 - 10.1038/s41598-019-45171-6

DO - 10.1038/s41598-019-45171-6

M3 - Article

C2 - 31227752

AN - SCOPUS:85067811373

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 9039

ER -